IBAB Ion Beam Applications SA

IBA and Jabil sign contract to install a Be-Wide X-ray solution in Mississippi, USA

IBA and Jabil sign contract to install a Be-Wide X-ray solution in Mississippi, USA

 

Louvain-la-Neuve, Belgium, February 25, 2025 –  (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial irradiation, and Jabil Inc. a global leader in engineering, manufacturing, and supply chain solutions, announced today they have signed a contract for the installation of a Be-Wide X-ray solution in a greenfield site in Byhalia, Mississippi, USA, to expand Jabil’s sterilization capabilities.

The Be Wide X-ray solution, powered by IBA’s Rhodotron® accelerator, will enhance Jabil's portfolio, offering advanced high-scale sterilization technology for a diverse range of medical devices. It includes a full-size pallet conveyor, Beagle production line control system, and Building Safety System.

Jabil went on to state that this investment in IBA’s Be Wide solution and their global network ensures efficiency, reliability, and scalability to meet global customer needs while maintaining high safety and compliance standards. It will allow them to support large-scale production with global capacity, quality, and integrated capabilities, including sterilization cycle documentation, logistics, and procurement.

Construction of the new Jabil facility is expected to be completed during the second half of 2026 and they expect full operational capability of the Be Wide solution in late 2027. IBA will install and test the system, as well as train Jabil’s team.

Mike Mahaz, Senior Vice President of Healthcare Division at Jabil, commented:” Jabil is pleased to partner with IBA to expand our sterilization services with industrial X-ray irradiation, strategically located near Memphis. IBA’s expertise ensures our X-ray services will operate with the utmost care and quality.”

Thomas Servais, President of IBA Industrial Solutions, added: “We are proud to support Jabil Healthcare on this transformative step. Our Be Wide X-ray Solution not only expands their global sterilization capabilities but also ensures they have the latest in scalable irradiation processing for a complete range of products, meeting the growing demands of the medical device industry.”

The typical price for a Be Wide X-ray solution with customization ranges from EUR 16 million to EUR 19 million, depending on the configuration and options.

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered to be the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

About JABIL

At Jabil (NYSE: JBL), we are proud to be a trusted partner for the world's top brands, offering comprehensive engineering, manufacturing, and supply chain solutions. With over 50 years of experience across industries and a vast network of over 100 sites worldwide, Jabil combines global reach with local expertise to deliver both scalable and customized solutions. Our commitment extends beyond business success as we strive to build sustainable processes that minimize environmental impact and foster vibrant and diverse communities around the globe. Discover more at .

CONTACTS

Olivier Lechien

Corporate Communication Director



ICR Consilium

Amber Fennell, Angela Gray, Lucy Featherstone

+44 (0) 20 3709 5700

Attachment



EN
25/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE

World's Leading Institutions and IBA launch Proton Therapy Academy to ...

World's Leading Institutions and IBA launch Proton Therapy Academy to shape the future of cancer care New global education initiative unveiled at 2025 PTCOG Annual Conference Louvain-la-Neuve, Belgium, 4 June 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces the launch of Proton Therapy Academy, a new global training and education initiative developed in partnership with prominent institutions in the field of proton therapy. The Academy has be...

 PRESS RELEASE

Des institutions mondiales de renom et IBA lancent la Proton Therapy A...

Des institutions mondiales de renom et IBA lancent la Proton Therapy Academy pour élaborer l'avenir des soins contre le cancer Nouvelle initiative mondiale de formation présentée lors de la conférence annuelle PTCOG 2025 Louvain-la-Neuve, Belgique, le 4 juin 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, annonce aujourd'hui le lancement de la Proton Therapy Academy, une nouvelle initiative de formation et d’éducation développée en parte...

 PRESS RELEASE

Iba – Acquisition of Own Shares - Completion of the Share Buyback Prog...

Iba – Acquisition of Own Shares - Completion of the Share Buyback Program Immediate Release – May 30th, 2025 Louvain-la-Neuve, Belgium, May 30th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until Decembe...

 PRESS RELEASE

IBA – ACQUISITION D’ACTIONS PROPRES - FIN DU PROGRAMME DE RACHAT D’ACT...

IBA – ACQUISITION D’ACTIONS PROPRES - FIN DU PROGRAMME DE RACHAT D’ACTIONS Publication immédiate – 30 mai 2025 Louvain-la-Neuve, Belgique, 30 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 24 mars 2025. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 650.000 actions ordinaires IBA selon les termes d'...

 PRESS RELEASE

Iba – Acquisition of Own Shares

Iba – Acquisition of Own Shares Immediate Release – May 26th, 2025 Louvain-la-Neuve, Belgium, May 26th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until December 31st, 2025, effective as from March 25th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch